Neurochemical and Cellular Reorganization of the Spinal Cord in a Murine Model of Bone Cancer Pain

Matthew J. Schwej, Prisca Honore, Scott D. Rogers, Janeen L. Salak-Johnson, Margaret L. Ramnaraine, Denis R. Clohisy, and Patrick W. Mantyh

1Neurosystems Center and Departments of Preventive Sciences, Psychiatry, Neuroscience, and Cancer Center, and 2Department of Orthopaedic Surgery and Cancer Center, University of Minnesota, Minneapolis, Minnesota 55455, and 3Veterans Administration Medical Center, Minneapolis, Minnesota 55417

The cancer-related event that is most disruptive to the cancer patient's quality of life is pain. To begin to define the mechanisms that give rise to cancer pain, we examined the neurochemical changes that occur in the spinal cord and associated dorsal root ganglia in a murine model of bone cancer. Twenty-one days after intramedullary injection of osteolytic sarcoma cells into the femur, there was extensive bone destruction and invasion of the tumor into the periostium, similar to that found in patients with osteolytic bone cancer. In the spinal cord, ipsilateral to the cancerous bone, there was a massive astrocyte hypertrophy without neuronal loss, an expression of dynorphin and c-Fos protein in neurons in the deep laminae of the dorsal horn. Additionally, normally non-noxious palpation of the bone with cancer induced behaviors indicative of pain, the internalization of the substance P receptor, and c-Fos expression in lamina I neurons. The alterations in the neurochemistry of the spinal cord and the sensitization of primary afferents were positively correlated with the extent of bone destruction and the growth of the tumor. This "neurochemical signature" of bone cancer pain appears unique when compared to changes that occur in persistent inflammatory or neuropathic pain states. Understanding the mechanisms by which the cancer cells induce this neurochemical reorganization may provide insight into peripheral factors that drive spinal cord plasticity and in the development of more effective treatments for cancer pain.

Key words: astrocyte; gliosis; nociception; primary afferents; sensitization; osteolysis

More than 500,000 patients in the United States died from cancer in 1998, and over 1 million patients suffer from cancer-related pain each year. Pain is the first symptom of cancer in 20–50% of all cancer patients, and 75–90% of advanced or terminal cancer patients must cope with chronic pain syndromes related to failed treatment and/or tumor progression (Portenoy and Lesage, 1999). The two most difficult cancer pains to treat are those related to invasion of peripheral nerves and destruction of bone. Breakthrough pain occurs frequently in both of these cancer-induced pain states and represents a serious and debilitating clinical problem (Mercadante and Arcuri, 1998; Portenoy et al., 1999). In total, these two forms of cancer pain account for ~75% of all chronic cancer pain (Koehler, 1990; Banning et al., 1991; Coleman, 1998; Foley, 1999).

The greatest obstacle to developing new treatments for persistent cancer pain and/or optimally coordinating existing treatments is a paucity of knowledge of the basic neurobiology of cancer pain. There is no well accepted animal model of cancer pain, and the majority of what we know about the neurochemistry of cancer pain has been obtained from clinical studies on how to best manage pain in patients with cancer. Studies on the sensory and sympathetic innervation of human tumors suggest that there is relatively little direct neural innervation of tumors (O'Connell et al., 1998). However, malignant cells are known to secrete prostaglandins, cytokines, epidermal growth factor, transforming growth factor, and platelet-derived growth factor, many of which have been shown to excite primary afferent nociceptors (Mundy, 1988; Goni and Tolis, 1993; Hingtgen and Vasko, 1994; Suzuki and Yamada, 1994; Vasko et al., 1994; Watkins et al., 1994; Safieh-Garabedian et al., 1995; Hingtgen et al., 1995; Vasko, 1995; Woolf et al., 1997). Additionally, macrophages, which can represent >20–30% of the cells in the tumor mass (McBride, 1986), produce factors such as tumor necrosis factor and interleukin-1, which have been reported to excite primary afferent neurons (Watkins et al., 1994; Safieh-Garabedian et al., 1995; Woolf et al., 1997; Sorkin et al., 1997).

To determine the neurochemical mechanisms that give rise to cancer pain, we have developed a model of bone cancer pain that shares many similarities with human cancer-induced bone pain (Mercadante, 1997). Tumors that most frequently give rise to metastatic bone pain are those originating from breast, lung, ovarian, and prostate cancers (Coleman and Rubens, 1985, 1987). After development of the model, we have characterized the extent of cancer-induced bone destruction, the sensory innervation of the bone, the animal behavior indicative of pain, and the neurochemical changes that occur in the spinal cord and primary afferent neurons that may be involved in the generation and maintenance of cancer pain.
Additional controls consisted of naïve mice (20) were injected directly into the medullary cavity of the distal femur.

MATERIALS AND METHODS

Strain of mouse and injection of osteolytic cells. Experiments were performed on adult B6C3-Fe-a/a wild-type and C3H/HeJ normal mice, 5- to 6-weeks-old, weighing 20–25 gm (Jackson Laboratories, Bar Harbor, ME). These strains were chosen for their histocompatibility with the NCTC 2472 tumor line [American Type Culture Collection (ATCC), Rockville, MD], previously shown to form lytic lesions in bone after intramedullary injection (Clohisy et al., 1995, 1996a).

Tumor cells were maintained in NCTC 135 media containing 10% horse sera (HyClone, Logan, UT) and passaged weekly according to ATCC recommendations. Tumor-bearing animals were generated as previously published (Clohisy et al., 1996a,b). Briefly, mice were anesthetized with sodium pentobarbital (50 mg/kg, i.p.), and a left knee arthrotomy was performed. Tumor cells, 10⁵ in 20 μl of a minimal essential medium (αMEM) containing 1% bovine serum albumin (BSA) (tumor; n = 40) or 20 μl of αMEM containing 1% BSA alone (sham; n = 20) were injected directly into the medullary cavity of the distal femur. Additional controls consisted of naïve mice (n = 8) and mice with 10⁵ 2472 tumor cells 20 μl of αMEM containing 1% BSA implanted into the quadriceps muscle (n = 10). The mice were housed in accordance with National Institutes of Health guidelines and kept in a vivarium, maintained at 22°C, with a 12 hr alternating light/dark cycle and were given food and water ad libitum. All procedures were approved by the Animal Care Committees at the University of Minnesota.

Behavioral analysis. To evaluate the development of a nociceptive state, animals were observed at 21 d after injection as they were handled and when they were stimulated with a normally non-noxious mechanical stimulation, which consisted of a light palpation of the distal femur every second for 2 min (for sham and tumor injection inside the femur) and light palpation of the tumor itself (for tumor injected into the quadriceps muscle). Nocicceptive behaviors were recorded during and after the 2 min palpation period. Each animal was given a score of 0–5. While the injected hindlimb was being palpated, the scoring of each animal was characterized as follows: no reaction during palpation (0); guarding of the hindlimb (1); guarding and strong withdrawal of the hindlimb (2); guarding, strong withdrawal, and fighting (3); guarding, strong withdrawal, fighting, and audible vocalization (4); and guarding, strong withdrawal, fighting, audible vocalization, and intense biting (5).

Killing and processing of tissue. Animals were killed 21 d after tumor implantation, the spinal cords and dorsal root ganglia (DRGs) were processed for immunohistochemical analysis, and femora were processed for evaluation of bone destruction. Twenty-one days was chosen as the time point because significant, but variable, osteolysis had previously been observed between 14 and 21 d after injection of the 2472 osteolytic sarcoma cells (Clohisy et al., 1995). In some animals, the cancer-bearing-limb was palpated 5 min [substance P receptor (SPR) internalization] or 1 hr (c-Fos expression) before killing. After these manipulations, the animals were deeply anesthetized with pentobarbital (50 mg/kg, i.p.) and perfused intracardially with 12 ml of 0.1M PBS followed by 20 ml of 4% formaldehyde in PBS. Both ipsilateral and contralateral femora, spinal cord segments L1–S2, and the L4 and L5 DRGs were removed, post-fixed for 16 hr in the perfusion fixative, and cryoprotected for 24 hr in 30% sucrose in 0.1 M PBS.

Assessing the extent of bone destruction. The extent of bone destruction (osteolysis) in tumor-injected femora was radiologically assessed using either standard x-ray film (TMG/RA; Eastman Kodak, Rochester, NY) or Faxitron analysis (Specimen Radiography System, model MX-20; Faxitron x-ray Corporation, Wheeling, IL) using Kodak film X-Omat TL. Radiographs of the femur (Fig. 1C) revealed loss of bone density caused by tumor osteolysis. The loss of bone density was quantified on a scale of 0–3. Images 0–3 are examples of each state of destruction: (0) normal bone; (1) minor loss of bone in medullary canal (arrow); (2) substantial loss of bone in medullary canal with some destruction of the distal femur (arrow); (3) substantial loss of bone in medullary canal with major structural destruction of the distal femur (arrow). Scale bars: A, B, 200 μm; C, 2 mm.

Figure 1. Quantification of bone destruction after injection of osteolytic sarcoma cells into the femoral intramedullary space. Hematoxylin–eosin staining of normal (A) and 21 d sarcoma-bearing (B) femora, showing the replacement of the darkly stained marrow cells with the more lightly stained sarcoma cells that have induced bone destruction and grown through the bone (arrowhead) and beyond (arrow). Radiographs of the femur (C) showing the progressive loss of bone caused by tumor growth. Bone destruction was quantified on a 0–3 scale based on the loss of bone. Images 0–3 are examples of each state of destruction: 0, normal bone; 1, minor loss of bone in medullary canal (arrow); 2, substantial loss of bone in medullary canal with some destruction of the distal femur (arrow); 3, substantial loss of bone in medullary canal with major structural destruction of the distal femur (arrow). Scale bars: A, B, 200 μm; C, 2 mm.
on gelatin-coated slides. The peristium was teased off the bone and processed as a whole mount.

Tissue sections were incubated for 30 min at room temperature in a blocking solution of 1% normal donkey serum in PBS with 0.3% Triton-X100 and then incubated overnight at room temperature in the primary antisera. Markers of (1) primary afferent fibers, substance P (SP); polyclonal rat anti-SP; 1:2000; PharMingen, San Diego, CA), isolectin B4 (IB4; Bandeiraea simplicifolia; 1:180; Sigma, St. Louis, MO), and neuropeptide Y (NPY; polyclonal rabbit anti-NPY; 1:5000; Sigma); (2) spinal cord neurons, substance P receptor (SPR; polyclonal rabbit anti-SPR; 1:5000; raised in our laboratory), neuronal marker (NeuN; polyclonal rat anti-NeuN; 1:75; Chemicon, Temecula, CA), protein kinase C gamma (PKCγ; polyclonal rabbit anti-PKCy; 1:1000; Santa Cruz Biotechnology, Santa Cruz, CA), dynorphin (DYN; polyclonal guinea pig anti-DYN; 1:10000; gift from Dr. J. Porreca, University of Arizona), and c-Fos (c-Fos; polyclonal rabbit anti-c-Fos; 1:30000; Santa Cruz Biotechnology); (3) motor neurons, NeuN, and choline acetyl transferase (ChAT; polyclonal rabbit anti-ChAT; 1:1000; Chemicon); (4) astrocytes, glial fibrillary acidic protein (GFAP; polyclonal rabbit anti-GFAP; 1:600; Dakopatts, Copenhagen, Denmark); and (5) microglia, OX-42 (polyclonal rat anti-Ox-42; 1:40; Chemicon) were used to stain spinal cord sections. DRG sections were stained with SP and IB4 and periosteum with c-Fos and IB4. Cytoskeletal markers (clonal rat anti-NeuN; 1:75; Chemicon, Temecula, CA), protein kinase C gamma (PKCγ; polyclonal rabbit anti-PKCy; 1:1000; Santa Cruz Biotechnology, Santa Cruz, CA), dynorphin (DYN; polyclonal guinea pig anti-DYN; 1:10000; gift from Dr. J. Porreca, University of Arizona), and c-Fos (c-Fos; polyclonal rabbit anti-c-Fos; 1:30000; Santa Cruz Biotechnology). To control for the possibility that staining intensities might vary between experiments, control sections of normal mouse spinal cord were included in each run of staining and served as a standard for immunofluorescence measurements.

Quantification of immunofluorescence levels and SPR internalization. Using an MRC-1024 confocal imaging system (Bio-Rad, Hercules, CA) and an Olympus BH-2 microscope equipped for epifluorescence (Mantyh et al., 1995), sections from the lumbar spinal cord and DRGs were analyzed by fluorescent and confocal microscopy to characterize immunofluorescence levels, number of immunoreactive cells, and palpatioinduced SPR internalization and spinal c-Fos expression.

Analyses were performed on the spinal cord at the lumbar level (L4) and on the L4 DRG because L4 DRG is one of the main groups of primary afferent neurons innervating the hindlimb (Molander et al., 1984; Molander and Grant, 1985; LaMotte et al., 1991). In addition, after palpation of the femur with tumor, SPR internalization and c-Fos protein expression were measured in the L4 level.

Immunointensity measurements for SPR were obtained using a 12 bit SPOT2 digital camera (Diagnostic Instruments, Sterling Heights, MI) on an Olympus BX-60 fluorescence microscope with Image Pro Plus version 3.0 software (Media Cybernetics, Silver Spring, MD). The response of the digital camera was measured using 540/560 nm Inspeck fluorescent bead standards (Molecular Probes, Eugene, OR). A ratio was established between the output of the camera and a given relative fluorescence of the beads. The camera response was determined to be linear, thus establishing that a doubling of the camera grayscale output represents a doubling of label present in the tissue.

For SPR internalization, sagittal sections were viewed through a 1 cm² eyepiece grid divided into 100 1 x 1 mm units. In cell bodies that express the SPR but have not internalized the SPR, SPR immunoreactivity is distributed on the plasma membrane. In contrast, in the neurons that have internalized the SPR, the cytoplasm contain bright, SPR immunoreactive endosomes. An endosome was defined as an intense SPR-immunoreactive intracellular organelle between 0.1 and 0.7 μm in diameter that was clearly not part of the external plasma membrane. In the normal unstimulated mouse spinal cord, nearly every lamina I neuron contained less than five SPR-immunoreactive endosomes per cell body. In the present study, neurons containing ≥20 endosomes were considered to be internally labeled. Importantly, because neurons with ≥20 endosomes were not counted as having undergone significant SPR internalization, it is possible that subtle changes in the magnitude of internalization were underestimated.

To study the laminar distribution of c-Fos and dynorphin expression,
bone (Iwasaki et al., 1995). Although CGRP fibers are found in all aspects of the bone, the structure with the richest CGRP innervation is the periosteum. Within the periosteum, CGRP fibers form a dense meshwork of interdigiting fibers, and when these fibers penetrate mineralized bone, they usually follow blood vessels. Although the periosteum is highly innervated, only occasional CGRP fibers were observed in the 2472 tumor mass in the intramedullary space of the bone, and those that were present were associated with blood vessels. The development of the sarcoma did not induce any obvious changes in the innervation of mineralized bone or periosteum, although the destruction of both mineralized bone and periosteum made it difficult to quantify changes that might have taken place. In naïve or sham-injected animals, 31 ± 5% of small cells were SP-immunoreactive (IR), whereas 73 ± 3% of small DRG neurons were IB4-IR, and these percentages did not significantly change in animals injected with sarcoma cells within the femur or within the quadriceps muscle (Table 1).

### Alterations in the spinal cord neurochemistry 21 d after tumor injection

Subpopulations of sensory neurons express either SP or can be labeled with the isoleucin IB4. SP-expressing primary afferent neurons terminate in laminae I-II of the dorsal horn of the spinal cord and neurons that are labeled with isoleucin IB4 are confined to lamina II. As in the DRGs, SP and IB4 immunofluorescent levels in the superficial spinal cord were not statistically different when comparing naïve, sham injections into the femur, sarcoma injection into the quadriceps muscle, or sarcoma injection into the femur (Fig. 2E, Table 1). In these four groups of animals, there was no change in NPY-IR or dynorphin-IR in laminae I-II (Fig. 2B, Table 1) nor any changes in the number or immunofluorescence levels of spinal cord neurons labeled with SPR in laminae I-II and III-IV, PKCγ in lamina II (Fig. 2F), or NeuN in the overall gray matter (Table 1). Additionally, the number of motor neurons labeled with NeuN or ChAT remained unchanged in these four groups (Table 1).

In contrast, there were three significant changes that occurred in the spinal cord of animals that received injection of 2472 sarcoma cells into the femur that were not observed in any of the other experimental groups. First, there was expression of dynorphin in a subpopulation of dorsal horn neurons located in laminae III-VI (5 ± 1 DYN-IR neurons per section; p < 0.001 compared to sham values of 0 ± 0 DYN-IR neurons per section; Fig. 2B, Table 1). This dynorphin accumulation was observed only in the spinal cord segments L3–L5 ipsilateral to bone destruction and peaked at spinal cord segment L4. This expression of dynorphin by neurons in the deep laminae of the spinal cord was positively

---

### Table 1. Neurochemical signature of bone cancer pain

<table>
<thead>
<tr>
<th></th>
<th>Sham-bone</th>
<th>Quadriceps</th>
<th>Bone</th>
<th>Bone</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Media injection</td>
<td>Tumor injection</td>
<td>ipsilateral side</td>
<td>ipsilateral side</td>
</tr>
<tr>
<td><strong>Spinal cord</strong> Primary afferents</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>SP Lam I–II (IF)</td>
<td>100.0 ± 13.2</td>
<td>129.7 ± 18.6</td>
<td>111.8 ± 5.0</td>
<td>105.3 ± 5.6</td>
</tr>
<tr>
<td>IB4 Lam III (IF)</td>
<td>100.0 ± 12.7</td>
<td>104.8 ± 17.3</td>
<td>143.7 ± 12.8</td>
<td>140.3 ± 13.3</td>
</tr>
<tr>
<td>NPY Lam I–II (IF)</td>
<td>100.0 ± 15.6</td>
<td>112.1 ± 9.4</td>
<td>110.4 ± 4.0</td>
<td>117.1 ± 10.2</td>
</tr>
<tr>
<td>DYN Lam I–II (IF)</td>
<td>100.0 ± 7.7</td>
<td>117.4 ± 7.5</td>
<td>103.3 ± 0.6</td>
<td>103.3 ± 0.6</td>
</tr>
<tr>
<td>SPR Lam I–II (IF)</td>
<td>100.0 ± 29.6</td>
<td>100.6 ± 8.8</td>
<td>143.4 ± 26.8</td>
<td>153.3 ± 27.5</td>
</tr>
<tr>
<td>PKCy Lam III (IF)</td>
<td>100.0 ± 14.7</td>
<td>100.1 ± 21.1</td>
<td>95.8 ± 22.7</td>
<td>85.3 ± 27.9</td>
</tr>
<tr>
<td>NeuN Lam I–X (IF)</td>
<td>100.0 ± 9.5</td>
<td>98.9 ± 4.2</td>
<td>93.4 ± 4.2</td>
<td>96.9 ± 4.4</td>
</tr>
<tr>
<td>DYN Lam III–VI (count)</td>
<td>0.0 ± 0.0</td>
<td>5 ± 1***</td>
<td>0.0 ± 0.0</td>
<td>3.2 ± 1.3</td>
</tr>
<tr>
<td>Lam I–II (count)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Basal Fos-IR</td>
<td>5.2 ± 2.1</td>
<td>0.7 ± 0.5</td>
<td>12.6 ± 2.3*</td>
<td>3.2 ± 1.3</td>
</tr>
<tr>
<td>Palpation induced Fos-IR</td>
<td>11.0 ± 3.6</td>
<td>0.5 ± 0.5</td>
<td>32.0 ± 6.0**</td>
<td>6.5 ± 2.3</td>
</tr>
<tr>
<td>Lam V–VI (count)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Basal Fos-IR</td>
<td>16.7 ± 3.2</td>
<td>1.0 ± 1.0</td>
<td>42.2 ± 4.8***</td>
<td>14.5 ± 4.6</td>
</tr>
<tr>
<td>Palpation induced Fos-IR</td>
<td>10.7 ± 4.2</td>
<td>1.5 ± 1.5</td>
<td>32.7 ± 6.3***</td>
<td>10.3 ± 5.2</td>
</tr>
<tr>
<td><strong>Glia</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>GFAP Lam I–X (IF)</td>
<td>100.0 ± 25.6</td>
<td>84.2 ± 26.9</td>
<td>359.9 ± 95.8**</td>
<td>95.3 ± 27.2</td>
</tr>
<tr>
<td>Oxa2 Lam I–X (IF)</td>
<td>100.0 ± 1.0</td>
<td>103.7 ± 0.5</td>
<td>99.6 ± 2.5</td>
<td>99.7 ± 2.1</td>
</tr>
<tr>
<td><strong>Motoneurons</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>NeuN motoneurons (count)</td>
<td>100.0 ± 5.8</td>
<td>104.9 ± 2.6</td>
<td>93.5 ± 3.2</td>
<td>96.3 ± 3.0</td>
</tr>
<tr>
<td>ChAT motoneurons (count)</td>
<td>100.0 ± 0.6</td>
<td>108.5 ± 9.1</td>
<td>102.1 ± 4.6</td>
<td>98.4 ± 5.9</td>
</tr>
<tr>
<td><strong>DRG</strong> SP (% of small neurons)</td>
<td>31.0 ± 4.9</td>
<td>29.8 ± 3.2</td>
<td>25.6 ± 2.5</td>
<td>33.7 ± 4.2</td>
</tr>
<tr>
<td>IB4 (% of small neurons)</td>
<td>73.3 ± 3.1</td>
<td>62.9 ± 0.8</td>
<td>72.8 ± 5.8</td>
<td>72.1 ± 6.8</td>
</tr>
</tbody>
</table>

For the spinal cord, all results are expressed as percentage of sham values except that of Fos-IR and dynorphin-IR, which are expressed as absolute numbers. Values are for immunofluorescence levels (IF) or number of neurons (count) for neurochemical markers that are found in the spinal cord that include substance P (SP), isoleucin B4 (IB4), neuropeptide Y (NPY), dynorphin (DYN), substance P receptor (SPR), protein kinase Cγ (PKCy), c-Fos immunoreactivity (Fos-IR), an astrocyte marker (GFAP), a microglia marker (Oxa2), a neuronal marker (NeuN), and choline acetyl transferase (ChAT). For DRG neurons, the results are expressed as percentage of small neurons expressing SP or IB4 in each experimental group. Note that the only significant changes observed are in the spinal cord ipsilateral to the femur that received injection of osteolytic sarcoma cells, and these changes were correlated with the extent of bone destruction. One-way ANOVA and Fisher’s PLSD, *p < 0.05, **p < 0.01 compared to the sham group.
Figure 2. Neurochemical changes in the dorsal horn of the spinal cord 21 d after unilateral injection of an osteolytic sarcoma in the intramedullary space of the femur. Confocal images of coronal sections of the L4 spinal cord illustrate the distribution of the astrocyte marker GFAP (A); DYN with arrows indicating the cell bodies expressing this pro-hyperalgesic peptide (B); c-Fos protein in the basal unstimulated state (C); (Figure legend continues)
and significantly correlated to the extent of bone destruction ($r = 0.97; p < 0.0001$).

The second major change was in the expression of c-Fos protein in the spinal cord. In the unstimulated mouse, there are relatively few spinal neurons that express the c-Fos protein. Thus, very few Fos-IR neurons were observed in the spinal cord in naive animals, animals that received sham injection into the femur, or animals that received injection of 2472 sarcoma cells into the quadriceps muscle (Table 1). In contrast, 21 d after injection of 2472 sarcoma cells into the femur, without any additional somatosensory stimulation, there was a significant increase in the number of spinal cord neurons that express c-Fos protein in laminae V-VI of the dorsal horn (Fig. 2C, Table 1). This c-Fos expression was observed only in the spinal cord segments L3–L5, and the number of neurons expressing c-Fos peaked at spinal cord segment L4, ipsilateral to bone destruction. This increase was positively and significantly correlated with the extent of bone destruction ($r = 0.95; p < 0.0002$; see Fig. 4A).

The third and most striking neurochemical change that occurred in animals injected with 2472 sarcoma cells in the femur was a massive astrogliosis that occurred in the ipsilateral spinal cord segments that receive primary afferent input from the cancerous femur. This astrogliosis was quantified using the astrocyte marker GFAP. In the animals with sarcoma injection into the femur, overall GFAP immunofluorescence levels were $359.9 \pm 95.8\%$ of sham values ($p < 0.01$; Figs. 2A, 3A). This increase in GFAP labeling was observed in lumbar segments L2–L5 with a peak in L4 (Fig. 3A), ipsilateral to bone destruction, and was not associated with any loss of neurons because the labeling with the neuronal marker NeuN remained unchanged (Fig. 3D,E). This increase in GFAP labeling was highest in laminae V-VI, but a significant increase was also observed throughout all the spinal laminae in sarcoma-injected animals. GFAP levels were $137.4 \pm 9.5\%$ (laminae I-II), $238.9 \pm 36.1\%$ (laminae III-IV), $655.9 \pm 141.2\%$ (laminae V-VI), $493.5 \pm 126.1\%$ (ventral region) of sham values; $p < 0.05; p < 0.05; p < 0.001$; and $p < 0.001$, respectively). This increase in GFAP appeared to represent a hypertrophy of the astrocytes because the cell bodies were enlarged, and the distal processes of the astrocytes were longer and exhibited extensive arborization as compared to sham animals, animals with injection of 2472 sarcoma cells into the quadriceps muscle, or the contralateral spinal cord of the animals receiving injection of 2472 sarcoma cells into the femur (Fig. 3B,D). This astrogliosis was positively and significantly correlated to the extent of bone destruction ($r = 0.695; p < 0.0001$; Fig. 4A). In contrast, the level of OX-42 immunoreactivity that labels microglia remained unchanged (Table 1).

**Effects of normally non-noxious palpation in the spinal cord in normal mice and mice with bone cancer**

In the spinal cord, the highest concentration of SPR-expressing cells is found in lamina I with other SPR-expressing cells also being present in laminae III-V and X. In the normal unstimulated animal, most of the SPR-IR is associated with the plasma membrane with few SPR-IR endosomes present in the cytoplasm. Non-noxious palpation of the distal femur did not induce spinal SPR internalization in naive animals or animals with sham injection into the femur, nor did non-noxious palpation of the tumor in animals where the sarcoma cells had been injected into the quadriceps muscle (Figs. 5A, 6A). In contrast, this normally non-noxious stimulation induced SPR internalization in a significant number of SPR-expressing lamina I neurons in animals that had received sarcoma injection into the femur (Fig. 5B). SPR internalization was observed in both the dendrites and cell body of SPR neurons localized in lumbar segments L3–L5 ipsilateral to the palpation. After a normally non-noxious stimulation, $63 \pm 8\%$ of the SPR-expressing lamina I neurons showed SPR internalization (Fig. 6A; $p < 0.01$ compared to sham values). No SPR internalization was detected in SPR-IR neurons located in deeper laminae. The number of SPR-internalized lamina I neurons was positively and significantly correlated to the extent of bone destruction ($r = 0.91; p < 0.002$).

Normally non-noxious mechanical stimulation (palpation) of the distal femur also induced a significant increase in the number of c-Fos-expressing lamina I neurons in animals with sarcoma cells injected into their femur, whereas the same stimulation did not induce any significant c-Fos expression in animals that received sham injection in the femur or in animals that received sarcoma injection in the quadriceps muscle (Fig. 6B, Table 1). Non-noxious palpation induced $32 \pm 6$ of c-Fos-IR lamina I neurons per section ($p < 0.01$ compared to sham values and $p < 0.001$ compared to contralateral side). Non-noxious palpation induced c-Fos expression in neurons located principally in the lateral part of laminae I-II in lumbar segments L3–L5, peaking at L4 (Fig. 3D) which has previously been shown to correspond to the region of the dorsal horn that receives primary afferent input from the femur. The number of palpation-induced c-Fos-IR lamina I neurons was positively and significantly correlated to the extent of bone destruction ($r = 0.78; p < 0.005$).

**DISCUSSION**

A model for bone cancer pain?

In assessing any experimental animal model, it is important to determine how well the model approximates the human disease. The most common symptom of bone metastases in humans is bone pain. Bone destruction, which causes this pain, can lead to pathological fractures and/or hypercalcemia (Lipton, 1997; Mundy, 1997; Coukell and Markham, 1998; Fulfar et al., 1998). Over weeks or months, as the tumor grows and stimulates bone destruction, the pain progressively becomes more severe. Cancer-induced bone destruction causes an ongoing pain that is referred to the affected bone and is characterized as initially constant and dull in character. With increased bone destruction and time, the pain intensifies and can incapacitate the affected individual. As bone destruction progresses, acute pain is frequently observed to the affected bone and is characterized as initially constant and dull in character. With increased bone destruction and time, the pain intensifies and can incapacitate the affected individual. As bone destruction progresses, acute pain is frequently observed to the affected bone and is characterized as initially constant and dull in character. With increased bone destruction and time, the pain intensifies and can incapacitate the affected individual. As bone destruction progresses, acute pain is frequently observed to the affected bone and is characterized as initially constant and dull in character. With increased bone destruction and time, the pain intensifies and can incapacitate the affected individual. As bone destruction progresses, acute pain is frequently observed to the affected bone and is characterized as initially constant and dull in character. With increased bone destruction and time, the pain intensifies and can incapacitate the affected individual. As bone destruction progresses, acute pain is frequently observed to the affected bone and is characterized as initially constant and dull in character. With increased bone destruction and time, the pain intensifies and can incapacitate the affected individual. As bone destruction progresses, acute pain is frequently observed to the affected bone and is characterized as initially constant and dull in character. With increased bone destruction and time, the pain intensifies and can incapacitate the affected individual. As bone destruction progresses, acute pain is frequently observed to the affected bone and is characterized as initially constant and dull in character. With increased bone destruction and time, the pain intensifies and can incapacitate the affected individual. As bone destruction progresses, acute pain is frequently observed to the affected bone and is characterized as initially constant and dull in character. With increased bone destruction and time, the pain intensifies and can incapacitate the affected individual. As bone destruction progresses, acute pain is frequently observed to the affected bone and is characterized as initially constant and dull in character. With increased bone destruction and time, the pain intensifies and can incapacitate the affected individual. As bone destruction progresses, acute pain is frequently observed to the affected bone and is characterized as initially constant and dull in character. With increased bone destruction and time, the pain intensifies and can incapacitate the affected individual. As bone destruction progresses, acute pain is frequently observed to the affected bone and is characterized as initially constant and dull in character. With increased bone destruction and time, the pain intensifies and can incapacitate the affected individual. As bone destruction progresses, acute pain is frequently observed to the affected bone and is characterized as initially constant and dull in character. With increased bone destruction and time, the pain intensifies and can incapacitate the affected individual. As bone destruction progresses, acute pain is frequently observed to the affected bone and is characterized as initially constant and dull in character. With increased bone destruction and time, the pain intensifies and can incapacitate the affected individual. As bone destruction progresses, acute pain is frequently observed to the affected bone and is characterized as initially constant and dull in character. With increased bone destruction and time, the pain intensifies and can incapacitate the affected individual. As bone destruction progresses, acute pain is frequently observed to the affected bone and is characterized as initially constant and dull in character. With increased bone destruction and time, the pain intensifies and can incapacitate the affected individual. As bone destruction progresses, acute pain is frequently observed to the affected bone and is characterized as initially constant and dull in character. With increased bone destruction and time, the pain intensifies and can incapacitate the affected individual. As bone destruction progresses, acute pain is frequently observed to the affected bone and is characterized as initially constant and dull in character. With increased bone destruction and time, the pain intensifies and can incapacitate the affected individual. As bone destruction progresses, acute pain is frequently observed to the affected bone and is characterized as initially constant and dull in character.
Figure 3. Confocal images showing the increase in the astrocyte marker GFAP in coronal sections of the L4 spinal cord 21 d after injection of osteolytic sarcoma cells into the intramedullary space of the femur. In A–C, the GFAP is bright orange, and in D and E, GFAP is green, and the NeuN staining (which labels neurons) is red. A low-power image (A) shows that the upregulation of GFAP is almost exclusively ipsilateral to the femur with cancer, with a small increase in the contralateral spinal cord in lamina X. Higher magnification of GFAP contralateral (B, D) and ipsilateral (C, E) to the femur with cancer shows that on the ipsilateral side, there is marked hypertrophy of astrocytes characterized by an increase in both the size of the astrocyte cell bodies and the extent of the arborization of their distal processes. Additionally, this increase in GFAP (green) is observed without a detectable loss of neurons, because NeuN (red) labeling remains unchanged (D, E). These images, from 60-μm-thick tissue, are projected from six optical sections acquired at 4 μm intervals with a 20× lens. Scale bars: A, 200 μm (projected from 12 optical sections acquired at 0.8 μm intervals with a 100× lens); B, C, 20 μm (projected from 10 optical sections acquired at 0.8 μm intervals with a 60× lens); D, E, 30 μm.
In humans, the extent of bone destruction, and particularly ongoing osteolytic activity, is correlated with the severity and the frequency of breakthrough pain (Adami, 1997). The murine model we have developed appears to share many features of human bone cancer-induced pain. The osteolytic sarcoma cell line used in this study aggressively destroys bone and provides localized pathological findings found in human osteolytic bone cancer (Clohisy et al., 1995, 1996). Mice with bone cancer exhibit painful behavior in the form of guarding of the affected limb, and this behavior correlates with the extent of bone destruction. Severe acute pain is also observed in mice once significant bone destruction has occurred, because normally non-noxious palpation of the affected bone results in behaviors indicative of severe pain, and this severe pain is again correlated with the extent of bone destruction. These results suggest that this murine model shares key features with human bone cancer-induced pain.

What factors contribute to bone cancer pain?

In both experimental animals and humans, primary afferent sensory neurons innervate mineralized bone and the periosteum, a fibrous tissue covering the outside surface of the bone. What is clear from the present and previous studies is that while mineralized bone and the marrow are innervated by sensory neurons, this innervation is sparse compared to the sensory innervation of the tumor itself has been explored in the present and previous studies, and the general conclusions from these studies is that while the occasional sensory fiber can be observed innervating the tumor, this innervation is sparse and when present, is usually associated with the blood vessels that vascularize the tumor (O’Connell et al., 1998).

In light of the sensory innervation of the bone and periosteum and our understanding of tumor and bone biology, what drives bone cancer pain and why does this type of pain increase so dramatically over time? Most osteolytic tumors release a variety of factors that induce excessive osteoclast activity (Taube et al., 1994; Yoneda et al., 1994; Clohisy et al., 1995, 1996a,b; Clohisy and Ramnaraine, 1998). Osteoclasts destroy bone by forming an acidic extracellular compartment at sites of bone resorption.

With continued tumor-driven osteoclast bone resorption, the
neurons with sarcoma cells injected into the femur (sham injection without palpation). One-way ANOVA and Fisher’s p

animals with sarcoma cells injected into the quadriceps muscle, but does in c-Fos expression or SPR internalization in sham animals or in animals

sarcoma injection into the quadriceps muscle, or sarcoma injection into

c-Fos expression or SPR internalization in sham animals or in animals

injected with sarcoma cells into the quadriceps muscle, but does in animals with sarcoma cells injected into the quadriceps muscle, but does in animals with sarcoma cells injected into the femur (mean ± SEM). Note that palpation does not induce spinal c-Fos expression or SPR internalization in sham animals or in animals injected with sarcoma cells into the quadriceps muscle, but does in animals with sarcoma cells injected into the femur [p < 0.01 compared to sham animals with palpation and p < 0.001 compared to contralateral side (sham injection without palpation)]. One-way ANOVA and Fisher’s PLSD; **p < 0.01, ***p < 0.001 compared to contralateral side.

Figure 6. Normally non-noxious mechanical stimulation induces SPR internalization and c-Fos expression in lamina I spinal neurons ipsilateral to the femur injected with osteolytic sarcoma cells. Results are expressed as number of c-Fos-expressing neurons (A) and percentage of internalized SPR-expressing neurons (B) in lamina I after normally non-noxious mechanical stimulation (palpation) 21 d after media injection (sham), sarcoma injection into the quadriceps muscle, or sarcoma injection into the femur. Non-noxious palpation of the tumorous bone induces SPR internalization in lamina I neurons, in animals with either persistent inflammatory or neuropathic pain, normally non-noxious or noxious somatosensory stimulation now induces SPR internalization in lamina I neurons (Mantyh et al., 1995; Allen et al., 1997; Abbadie et al., 1997b; Honore et al., 1999). Similarly, whereas in the normal animal, noxious stimulation is required to induce c-Fos expression in lamina I neurons (Hunt et al., 1987; Abbadie and Besson, 1993; Jasmin et al., 1994; Basbaum, 1994; Honore et al., 1995a; Doyle and Hunt, 1999), after extensive bone destruction, non-noxious palpation of the tumorous bone induces c-Fos expression. These data suggest that there is sensitization of primary afferent neurons in animals with bone cancer, and this sensitization is correlated with the extent of bone destruction and growth of the tumor.

Bone cancer also induces a profound reorganization of the spinal cord that may be reflective of a central sensitization that is frequently observed in persistent pain states. In the segments of the spinal cord that receive primary afferent input from the bone with cancer, and only in these segments, we observed massive astrocyte hypertrophy without neuronal loss and expression of the pro-hyperalgesic peptide dynorphin and c-Fos protein in a population of neurons located in the deep spinal laminae. What is remarkable about these alterations is the magnitude and localized nature of these changes in terms of spinal cord segments and being almost exclusively ipsilateral to the side of bone destruction.

Hypertrophy of spinal astrocytes has previously been reported after sciatic nerve injury (Garrison et al., 1991, 1994; Colburn et al., 1997). However, examination of the sciatic nerve that innervates the femur with cancer revealed no sign of direct physical injury, and astrocyte hypertrophy was not observed in sham-injected animals or when the tumor was growing exclusively outside the bone. Whether the massive astrocyte hypertrophy is involved in the generation and maintenance of bone cancer pain is unclear (Meller et al., 1994), but it has previously been shown that astrocytes express glutamate–aspartate transporters and thus are intimately involved in regulating the extracellular levels of excitatory amino acids (Hansson and Rönnbäck, 1991; Amundson et al., 1992; Levi and Patrizio, 1992; Miyake and Kitamura, 1992; Shao and McCarthy, 1994; Shibata et al., 1997; Sonnewald et al., 1997; Lehre and Danbolt, 1998). Additionally, astrocytes that have undergone hypertrophy have been shown to release a variety of cytokines and growth factors that can dramatically alter the surrounding neurochemical environment (Gadient et al., 1990; Aloisi et al., 1992; Constam et al., 1992; Maimone et al., 1993; Murphy et al., 1993; Pechán et al., 1993; Maeda et al., 1994; Schettini et al., 1994; Grimaldi et al., 1995, 1997, 1998; Corsini et al., 1996; Deroç et al., 1996; Hori et al., 1996; Kossmann et al., 1996; Shafer and Murphy, 1997; Bruno et al., 1998; Sinor et al., 1998). Indeed, the population of neurons that show upregulation of the pro-hyperalgesic neuropeptide dynorphin and increased c-Fos expression are in the deep laminae and in close proximity to the astrocytes showing marked hypertrophy. Although changes in c-Fos and especially dynorphin have been associated with changes observed in inflammatory and neuropathic pain states (Jadarola et al., 1988a,b; Ruda et al., 1988; Weihe et al., 1988; Drai sci and Jadarola, 1989; Noguchi et al., 1991; Abbadie and Besson, 1992; Wagner et al., 1993; Honore et al., 1995a,b; Abbadie et al., 1997b; Nichols et al., 1997; Catheline et al., 1999), these data suggest that bone cancer induces a profound neurochemical reorganization of the spinal cord that is directly correlated with the extent of cancer-induced bone destruction.

osteoclasts and tumor cells may increasingly come in contact with sensory nerve fibers in the bone and the richly innervated periosteum. Many primary afferent neurons that innervate the periosteum have been shown to express acid-sensing ion channels (Olson et al., 1998) and it is probable that the decrease in pH produced by both nearby osteoclasts (pH 4.5–4.8; Delaisse and Vaes, 1992) and tumor cells, which can maintain a slightly acidic extracellular pH (between 6.0 and 7.0, Griffiths, 1991; Gillies et al., 1994), directly sensitize and/or excite periosteal primary afferent fibers. In addition, tumor cells release an array of growth factors, cytokines, and chemokines, many of which have been reported to also directly excite an/or sensitize primary afferent fibers (Goni and Tolis, 1993; Suzuki and Yamada, 1994; Watkins et al., 1994; Safieh-Garabedian et al., 1995; Woolf et al., 1997).

In the present study, we used two markers, SPR internalization and c-Fos expression in lamina I neurons, to indirectly demonstrate that primary afferent neurons are sensitized after extensive tumor-induced bone destruction. In previous studies, it has been shown that, whereas in the normal animal, only noxious stimulation results in the release of SP and the subsequent internalization of the SPR in lamina I neurons, in animals with either persistent inflammatory or neuropathic pain, normally non-
Neurochemical signature of inflammatory, neuropathic, and bone cancer pain

In recent years, significant progress has been made in demonstrating that in different persistent pain states there are strikingly different neurochemical changes that occur in primary afferent neurons and the spinal cord (Hokfelt et al., 1994). These neurochemical differences mirror the fact that many analgesics are most efficacious in blocking a specific type of persistent pain (Fields, 1988, 1989). For example, morphine is efficacious in treating inflammatory pain, but not neuropathic pain caused by peripheral nerve injury (Ossipov et al., 1995a,b), and gabapentin is frequently effective in treating neuropathic but not inflammatory pain.

In comparing bone cancer pain to inflammatory or neuropathic pain, both the neurochemical changes that take place and the analgesics that are most effective in treating humans suggest that the mechanisms involved in the generation and maintenance of bone cancer pain are unique. For example, whereas SP levels in primary afferent neurons rise in inflammatory pain (Lembeck et al., 1984; Donaldson et al., 1992) and decrease in neuropathic pain (Noguchi et al., 1989; Garrison et al., 1993), they are not altered in bone cancer pain. Even more striking are the changes observed in astrocyte hypertrophy in the spinal cord. Astrocyte hypertrophy in the spinal cord is uncommon in most models of inflammatory pain and is only observed in neuropathic pain states when there has been significant injury to the peripheral nerve (Garrison et al., 1991, 1994). In contrast, although there is no evidence of direct injury to the peripheral nerve, massive astrocyte hypertrophy is observed in the bone cancer model.

The unique neurochemical reorganization of the spinal cord in bone cancer is mirrored by the clinical experience that analgesics that are efficacious in the relief of inflammatory or neuropathic pain are frequently ineffective at relieving advanced bone cancer pain. Understanding the distinct neurochemical events that are involved in the generation and maintenance of different persistent pain states should provide a mechanistic approach for understanding and developing novel therapies for unique persistent pain states such as cancer pain.

REFERENCES


